Privia Health Group, Inc. (PRVA) Stock Forecast
PRVA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.61 / 5 from 18 analysts
- Price target
- $31.47 average of analyst targets
- Upside to target
- +39.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.09
- 52-week range
- $19.10 – $28.10
PRVA analyst ratings
18 analystsNumber of analysts at each rating.
PRVA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRVA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.24 | $0.18 | $0.32 | $0.29 | −17.9% | 10 |
| Current fiscal year (2026) | $0.89 | $0.77 | $1.24 | $0.99 | −10.4% | 10 |
| Next fiscal year (2027) | $1.06 | $0.85 | $1.36 | $0.89 | +19.8% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRVA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $610.6M | $584.9M | $650.1M | +5.2% | 14 |
| Current fiscal year (2026) | $2.46B | $2.42B | $2.52B | +15.8% | 14 |
| Next fiscal year (2027) | $2.70B | $2.54B | $2.85B | +9.7% | 14 |
PRVA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRVA revenue: reported and forecast
PRVA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.26 | $0.25 | $0.24 | $0.24 | $0.24 | −7.6% | 5 up · 4 down |
| Current fiscal year (2026) | $0.95 | $0.95 | $0.88 | $0.88 | $0.89 | −6.8% | 3 up · 7 down |
| Next fiscal year (2027) | $1.10 | $1.10 | $1.06 | $1.06 | $1.06 | −3.1% | 5 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRVA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRVA beat in 8 of 12.
What analysts expect from PRVA
18 analysts cover Privia Health; their consensus rating is strong buy (4.61 on a 1–5 scale, where 5 is a strong buy). The average price target is $31.47, 39.7% above the latest close of $22.52. Analysts expect earnings of $0.89 per share for 2026, −10.4% from a year earlier. For 2027 the average estimate is $1.06 per share on revenue of $2.7 billion. Privia Health beat the EPS estimate in 8 of the last 12 quarters.
Related: PRVA income statement, PRVA key metrics, PRVA chart. See the PRVA stock overview for the latest quote and news.
PRVA forecast FAQ
What is Privia Health's price target?
The average analyst price target for Privia Health is $31.47, 39.7% above the latest close of $22.52.
Is Privia Health a buy, hold or sell?
Of 18 analysts covering Privia Health, 12 rate it a strong buy, 5 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Privia Health's EPS forecast?
Analysts forecast $0.89 per share for 2026 (range $0.77 to $1.24); for 2027 the estimate is $1.06.
What is Privia Health's revenue forecast?
The average revenue estimate for 2026 is $2.5 billion, growth of 15.8%; for 2027 it is $2.7 billion.
When does Privia Health report earnings?
Privia Health is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $0.09.
Does Privia Health usually beat earnings estimates?
Privia Health reported EPS at or above the analyst estimate in 8 of the last 12 quarters.